Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
August 27, 2017DOI: 10.1056/NEJMoa1707914
- Abstract
- Article
- References
- Citing Articles (1)
- Comments
- Metrics
BACKGROUND
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.- +++++++++++++++
CONCLUSIONS
Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)
No comments:
Post a Comment